BioMAdvanced Diagnostics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BioMAdvanced Diagnostics - overview
Established
2021
Location
Nantes, -, France
Primary Industry
Healthcare
About
Based in Nantes, France, and founded in 2021 by Frédéric Pette, Nicolas Bouler, Sophie Brouard, Richard Danger, and Jean-Michel Bouler, BioMAdvanced Diagnostics operates as a healthcare company that provides doctors with diagnostic aid tools in the context of personalized, predictive, and preventive medicine. In July 2023, BiomAdvanced Diagnostics raised EUR 1. 4 million in venture funding from Bpifrance, Pays de la Loire Développement, and Sodero Gestion. BioMAdvanced Diagnostics is a developer of clinical diagnostics and biomarker tests used to monitor patients' immune systems.
Furthermore, the company provides tests developed by the company provides diagnostic results, and identifies biomarkers to evaluate and diagnose the risk of transplant rejection, allowing clinicians to adapt to changing and modify their patients' treatment. The company plans to use the July 2023 funding to fuel its product development.
Current Investors
Pays de la Loire Développement, Pays de la Loire Participations, Atlantique Vendée Innovation
Primary Industry
Healthcare
Sub Industries
Diagnostic Equipment
Website
www.biomadvanced-diagnostics.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.